Double-blind, Placebo-controlled, Escalating Single-dose, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of THR-18 in Subjects With Acute Ischemic Stroke and Treated With tPA
Phase of Trial: Phase II
Latest Information Update: 14 May 2015
Price : $35 *
At a glance
- Drugs THR 18 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors D-Pharm
- 14 May 2015 Final results published in D-Pharm media release.
- 03 Feb 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 13 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov